Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

被引：0
|
作者：
Wang, Z. [1 ]
Hu, X. [1 ]
Wang, B. [1 ]
Wang, L. [1 ]
Zhang, J. [1 ]
Wang, H. [1 ]
Liu, G. [1 ]
Hu, Z. [1 ]
Wu, J. [1 ]
Shao, Z. [1 ]
机构：
[1] Fudan Univ, Shanghai Med Coll, Canc Hosp, Shanghai 200433, Peoples R China
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-06
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Prclineinary results report of a phase II trial
    Wang, Z.
    Hu, X.
    Chen, L.
    Wang, J.
    Wang, H.
    Wang, L.
    Liu, G.
    Hu, Z.
    Wu, J.
    Zhimin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Zhao, Mingchuan
    Miao, Haitao
    Jin, Juan
    Hu, Xichun
    Wang, Biyun
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [4] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
    Gong, Chengcheng
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Zhang, Sheng
    Tao, Zhonghua
    Li, Ting
    Zhao, Yannan
    Li, Yi
    Wang, Biyun
    Hu, Xichun
    CANCER RESEARCH, 2018, 78 (04)
  • [5] Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
    Zhang, Jian
    Wang, Zhonghua
    Hu, Xichun
    Wang, Biyun
    Wang, Leiping
    Yang, Wentao
    Liu, Yang
    Liu, Guangyu
    Di, Genhong
    Hu, Zhen
    Wu, Jiong
    Shao, Zhimin
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (01) : 204 - 211
  • [6] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Wang, Biyun
    Sun, Tao
    Zhao, Yannan
    Wang, Shusen
    Zhang, Jian
    Wang, Zhonghua
    Teng, Yue-E
    Cai, Li
    Yan, Min
    Wang, Xiaojia
    Jiang, Zefei
    Pan, Yueyin
    Luo, Jianfeng
    Shao, Zhimin
    Wu, Jiong
    Guo, Xiaomao
    Hu, Xichun
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Biyun Wang
    Tao Sun
    Yannan Zhao
    Shusen Wang
    Jian Zhang
    Zhonghua Wang
    Yue-E Teng
    Li Cai
    Min Yan
    Xiaojia Wang
    Zefei Jiang
    Yueyin Pan
    Jianfeng Luo
    Zhimin Shao
    Jiong Wu
    Xiaomao Guo
    Xichun Hu
    Nature Communications, 13
  • [8] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
    Montagna, Emilia
    Bagnardi, Vincenzo
    Cancello, Giuseppe
    Sangalli, Claudia
    Pagan, Eleonora
    Iorfida, Monica
    Mazza, Manuelita
    Mazzarol, Giovanni
    Dellapasqua, Silvia
    Munzone, Elisabetta
    Goldhirsch, Aaron
    Colleoni, Marco
    BREAST CARE, 2018, 13 (03) : 177 - 181
  • [9] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.
    Karthaus, M.
    Poddubnaya, I.
    Churilova, L.
    Khasanov, R.
    Veremeychuk, T.
    Rumyantseva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, B.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [10] Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer
    Zhang, J.
    Lin, Y.
    Sun, X. J.
    Wang, B. Y.
    Wang, Z. H.
    Luo, J. F.
    Wang, L. P.
    Zhang, S.
    Cao, J.
    Tao, Z. H.
    Wu, J.
    Shao, Z. M.
    Yang, W. T.
    Hu, X. C.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1741 - 1747
12345